DEEP TRACK CAPITAL
Deep Track Capital is an investment firm focused exclusively on the life sciences industry.
DEEP TRACK CAPITAL
Status:
Active
Contact:
(203) 409 0810
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Google Maps GStatic Google Static Content
Similar Organizations
Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Current Employees Featured
David E. Kroin
David E. Kroin Founder & Chief Investment Officer @ Deep Track Capital Founder & Chief Investment Officer
Rebecca Luse
Rebecca Luse Principal @ Deep Track Capital Principal 2021-01-01
Mitchell Kaye
Mitchell Kaye Business Development and Strategy @ Deep Track Capital Business Development and Strategy 2021-01-01
Founder
David E. Kroin
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-09-02 | Abivax | Deep Track Capital investment in Post-IPO Equity - Abivax | 49.2 M EUR |
2022-08-09 | Heron Therapeutics | Deep Track Capital investment in Post-IPO Equity - Heron Therapeutics | 76.5 M USD |
2022-08-01 | ShouTi | Deep Track Capital investment in Series B - ShouTi | 33 M USD |
2022-07-26 | Carmot Therapeutics | Deep Track Capital investment in Series D - Carmot Therapeutics | 160 M USD |
2022-01-25 | Metagenomi | Deep Track Capital investment in Series B - Metagenomi | 175 M USD |
2022-01-16 | Third Harmonic Bio | Deep Track Capital investment in Series B - Third Harmonic Bio | 105 M USD |
2021-11-15 | Tricida | Deep Track Capital investment in Post-IPO Equity - Tricida | 42 M USD |
2021-11-09 | Arbor Biotechnologies | Deep Track Capital investment in Series B - Arbor Biotechnologies | 215 M USD |
2021-09-09 | Obsidian Therapeutics | Deep Track Capital investment in Series B - Obsidian Therapeutics | 115 M USD |
2021-08-24 | Dice Therapeutics | Deep Track Capital investment in Series C - Dice Therapeutics | 60 M USD |